What is Envveno Medical Corporation's earnings per share (EPS)?

Envveno Medical Corporation (NVNO) reported diluted earnings per share of $-33.06 for fiscal year 2025. This represents a 25.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Envveno Medical Corporation Financials

NVNO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Envveno Medical Corporation (NVNO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NVNO FY2025 2026-05-06

enVVeno remains an equity-funded development business whose main operating mechanic is turning liquid assets into time for R&D.

Between FY2023 and FY2025, operating cash burn improved only modestly, from -$18.9M to -$15.6M. With financing inflows only $1.0M in FY2025 while total assets fell to $29.6M, the company was buying time by consuming prior resources rather than replenishing them.

The losses are high-quality losses in an accounting sense: FY2025 net loss of -$19.5M sits close to operating cash outflow of -$15.6M, so reported results are not being flattered by large non-cash items. Because capital spending was only $5K, minimal capital intensity means the cash need comes from staffing and development activity, not from building a heavy physical asset base.

The lightly encumbered balance sheet matters as much as the losses: liabilities of $2.4M against equity of $27.1M leave little sign of lender dependence. More importantly, near-term liquidity looks less constrained than the cash line alone suggests, with current assets of $28.8M against current liabilities of $2.1M.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Envveno Medical Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Envveno Medical Corporation carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 13.58, Envveno Medical Corporation holds $13.58 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Envveno Medical Corporation generates a -71.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -51.7% the prior year.

Piotroski F-Score Weak

1/9

Envveno Medical Corporation passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Envveno Medical Corporation generates $0.80 in operating cash flow (-$15.6M OCF vs -$19.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$20.8M

YoY+12.2%

Envveno Medical Corporation's EBITDA was -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.2% from the prior year.

Net Income

-$19.5M

YoY+10.8%

Envveno Medical Corporation reported -$19.5M in net income in fiscal year 2025. This represents an increase of 10.8% from the prior year.

EPS (Diluted)

$-33.06

YoY+25.8%

Envveno Medical Corporation earned $-33.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 25.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$15.6M

YoY+7.7%

Envveno Medical Corporation generated -$15.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 7.7% from the prior year.

Cash & Debt

$3.1M

YoY+74.7%

5Y CAGR-20.0%

Envveno Medical Corporation held $3.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

656,000

YoY+30.9%

Envveno Medical Corporation had 656,000 shares outstanding in fiscal year 2025. This represents an increase of 30.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-71.8%

YoY-20.0pp

5Y CAGR+56.9pp

Envveno Medical Corporation's ROE was -71.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.0M

YoY-18.5%

5Y CAGR+18.6%

Envveno Medical Corporation invested $10.0M in research and development in fiscal year 2025. This represents a decrease of 18.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY-86.5%

5Y CAGR-51.2%

Envveno Medical Corporation invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 86.5% from the prior year.

NVNO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$10.0M-18.5%	$12.2M-9.8%	$13.6M+37.0%	$9.9M+73.1%	$5.7M+34.7%	$4.3M
SG&A Expenses	$10.9M-5.7%	$11.6M-0.7%	$11.7M-22.4%	$15.0M+34.5%	$11.2M+128.7%	$4.9M
Operating Income	-$20.9M+12.3%	-$23.8M+5.6%	-$25.2M-1.2%	-$24.9M-47.6%	-$16.9M-84.9%	-$9.1M
Interest Expense	N/A	N/A	N/A	$161K+747.4%	$19K+408.2%	$4K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$19.5M+10.8%	-$21.8M+7.2%	-$23.5M+4.7%	-$24.7M-49.3%	-$16.5M-80.9%	-$9.1M
EPS (Diluted)	$-33.06+25.8%	$-44.53	$-1.91+13.2%	$-2.20	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.1M	N/A	$2.6M-10.6%	$2.9M+13.1%	$2.6M	N/A	$2.9M+1.2%	$2.8M
SG&A Expenses	$2.0M	N/A	$2.3M-44.7%	$4.2M+73.5%	$2.4M	N/A	$3.3M+25.9%	$2.6M
Operating Income	-$4.1M	N/A	-$4.9M+30.7%	-$7.0M-42.3%	-$5.0M	N/A	-$6.2M-13.1%	-$5.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.8M	N/A	-$4.5M+32.2%	-$6.7M-48.7%	-$4.5M	N/A	-$5.6M-13.8%	-$5.0M
EPS (Diluted)	$-5.89	N/A	$-0.23+30.3%	$-0.33+95.7%	$-7.75	N/A	$-0.35-12.9%	$-0.31

NVNO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$29.6M-34.2%	$45.0M-7.6%	$48.6M+16.7%	$41.7M-27.8%	$57.7M+447.5%	$10.5M
Current Assets	$28.8M-34.1%	$43.7M-6.8%	$46.9M+19.0%	$39.4M-28.4%	$55.0M+475.2%	$9.6M
Cash & Equivalents	$3.1M+74.7%	$1.8M-51.5%	$3.6M-20.5%	$4.6M-91.7%	$54.7M+486.3%	$9.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-13.0%	$2.8M+14.8%	$2.4M-17.0%	$2.9M-11.0%	$3.3M-4.2%	$3.4M
Current Liabilities	$2.1M+1.3%	$2.1M+52.8%	$1.4M-10.4%	$1.5M-3.2%	$1.6M-50.4%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$27.1M-35.6%	$42.2M-8.7%	$46.2M+19.3%	$38.7M-28.8%	$54.4M+666.5%	$7.1M
Retained Earnings	-$171.3M-12.8%	-$151.9M-16.8%	-$130.0M-22.1%	-$106.5M-30.1%	-$81.9M-25.3%	-$65.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$26.1M-11.7%	$29.6M-8.6%	$32.4M-11.6%	$36.6M-9.9%	$40.6M-9.7%	$45.0M-10.8%	$50.4M+22.9%	$41.0M
Current Assets	$25.5M-11.6%	$28.8M-8.5%	$31.5M-11.5%	$35.6M-9.8%	$39.5M-9.7%	$43.7M-10.8%	$49.1M+24.1%	$39.5M
Cash & Equivalents	$2.6M-15.3%	$3.1M+98.5%	$1.5M-24.5%	$2.0M-30.4%	$2.9M+67.4%	$1.8M-90.2%	$17.9M+652.7%	$2.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-3.4%	$2.4M-16.3%	$2.9M-17.5%	$3.5M+55.1%	$2.3M-18.8%	$2.8M-7.5%	$3.0M+17.2%	$2.6M
Current Liabilities	$2.1M+1.0%	$2.1M-11.6%	$2.4M-20.4%	$3.0M+81.5%	$1.7M-20.7%	$2.1M-6.0%	$2.2M+31.5%	$1.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$23.7M-12.5%	$27.1M-7.9%	$29.4M-10.9%	$33.1M-13.7%	$38.3M-9.1%	$42.2M-11.0%	$47.4M+23.3%	$38.4M
Retained Earnings	-$175.2M-2.2%	-$171.3M-2.2%	-$167.6M-2.8%	-$163.1M-4.3%	-$156.4M-3.0%	-$151.9M-4.3%	-$145.6M-4.0%	-$140.0M

NVNO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.6M+7.5%	-$16.8M+10.7%	-$18.9M-20.7%	-$15.6M-31.8%	-$11.8M-54.3%	-$7.7M
Capital Expenditures	$5K-86.5%	$37K+12.1%	$33K-71.3%	$115K-68.8%	$368K+104.1%	$180K
Free Cash Flow	-$15.6M+7.7%	-$16.9M+10.7%	-$18.9M-20.1%	-$15.7M-28.8%	-$12.2M-55.5%	-$7.9M
Investing Cash Flow	$15.9M+1087.7%	$1.3M+117.0%	-$7.9M+77.2%	-$34.6M-9289.7%	-$368K-104.1%	-$180K
Financing Cash Flow	$1.0M-92.5%	$13.6M-47.1%	$25.8M	N/A	$57.6M+282.1%	$15.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$3.2M+6.0%	-$3.4M+21.6%	-$4.4M-18.2%	-$3.7M+7.5%	-$4.0M+21.3%	-$5.1M-19.4%	-$4.3M-9.4%	-$3.9M
Capital Expenditures	N/A	$0	$0	N/A	N/A	$4K-55.6%	$9K-35.7%	$14K
Free Cash Flow	N/A	-$3.4M+21.6%	-$4.4M	N/A	N/A	-$5.1M-19.2%	-$4.3M-9.3%	-$3.9M
Investing Cash Flow	$2.8M-33.8%	$4.2M+14.5%	$3.7M+29.4%	$2.8M-45.7%	$5.2M+147.0%	-$11.1M-277.7%	$6.2M+56.6%	$4.0M
Financing Cash Flow	N/A	$782K	N/A	N/A	N/A	$0-100.0%	$13.6M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NVNO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-71.8%-20.0pp	-51.7%-0.8pp	-50.9%+12.8pp	-63.7%-33.3pp	-30.4%+98.3pp	-128.7%
Return on Assets	-65.9%-17.3pp	-48.5%-0.2pp	-48.4%+10.9pp	-59.2%-30.6pp	-28.6%+58.0pp	-86.7%
Current Ratio	13.58-7.3	20.88-13.4	34.23+8.5	25.78-9.1	34.84+31.8	3.00
Debt-to-Equity	0.09+0.0	0.07+0.0	0.05-0.0	0.08+0.0	0.06-0.4	0.48
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-16.2%	N/A	-15.4%+4.8pp	-20.3%-8.5pp	-11.8%	N/A	-11.9%+1.0pp	-12.9%
Return on Assets	-14.8%	N/A	-14.0%+4.3pp	-18.3%-7.2pp	-11.1%	N/A	-11.2%+0.9pp	-12.1%
Current Ratio	11.89-1.7	13.58+0.5	13.12+1.3	11.81-12.0	23.77+2.9	20.88-1.1	22.01-1.3	23.33
Debt-to-Equity	0.100.0	0.090.0	0.100.0	0.11+0.0	0.060.0	0.070.0	0.060.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Intelligent Bio Solutions Inc INBS

$6.1M

Nexalin Tech NXL

$8.1M

Ainos Inc AIMD

$11.3M

ALLURION TECHNOLOGIES INC ALUR

$10.0M

Beyond Air Inc XAIR

$5.1M

Frequently Asked Questions

Is Envveno Medical Corporation profitable?

No, Envveno Medical Corporation (NVNO) reported a net income of -$19.5M in fiscal year 2025.

What is Envveno Medical Corporation's EBITDA?

Envveno Medical Corporation (NVNO) had EBITDA of -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Envveno Medical Corporation's return on equity (ROE)?

Envveno Medical Corporation (NVNO) has a return on equity of -71.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Envveno Medical Corporation's free cash flow?

Envveno Medical Corporation (NVNO) generated -$15.6M in free cash flow during fiscal year 2025. This represents a 7.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Envveno Medical Corporation's operating cash flow?

Envveno Medical Corporation (NVNO) generated -$15.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Envveno Medical Corporation's total assets?

Envveno Medical Corporation (NVNO) had $29.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Envveno Medical Corporation's capital expenditures?

Envveno Medical Corporation (NVNO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Envveno Medical Corporation spend on research and development?

Envveno Medical Corporation (NVNO) invested $10.0M in research and development during fiscal year 2025.

How many shares does Envveno Medical Corporation have outstanding?

Envveno Medical Corporation (NVNO) had 656,000 shares outstanding as of fiscal year 2025.

What is Envveno Medical Corporation's current ratio?

Envveno Medical Corporation (NVNO) had a current ratio of 13.58 as of fiscal year 2025, which is generally considered healthy.

What is Envveno Medical Corporation's debt-to-equity ratio?

Envveno Medical Corporation (NVNO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Envveno Medical Corporation's return on assets (ROA)?

Envveno Medical Corporation (NVNO) had a return on assets of -65.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Envveno Medical Corporation's cash runway?

Based on fiscal year 2025 data, Envveno Medical Corporation (NVNO) had $3.1M in cash against an annual operating cash burn of $15.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Envveno Medical Corporation's Piotroski F-Score?

Envveno Medical Corporation (NVNO) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Envveno Medical Corporation's earnings high quality?

Envveno Medical Corporation (NVNO) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Envveno Medical Corporation?

Envveno Medical Corporation (NVNO) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.